TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
These findings uncover a TET2-AGO2 regulatory axis that integrates epigenetic remodeling, 3D genome reorganization, and leukemic fitness, and they highlight AGO2 as a potential biomarker and therapeutic target in myeloid leukemia.
Appeared: Sunday, October 25. Science Advances. Peer-reviewed journal.